Diseases / Celiac Disease
Celiac Disease
DiseaseCeliac disease is an autoimmune disorder triggered by gluten ingestion in genetically susceptible individuals, causing immune-mediated damage to the small intestine.
- Trials
- 325
- Recruiting
- 41
- Completed
- 184
- With results
- 19
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | 1 | — | — | — | 3 | — | — | 1 | — | — | 5 |
| Phase 1 | 1 | — | — | — | 18 | 1 | 1 | — | — | — | 21 |
| Phase 1/2 | — | — | — | — | 6 | 1 | — | — | — | — | 7 |
| Phase 2 | 3 | — | — | 2 | 21 | 3 | — | — | 5 | — | 34 |
| Phase 2/3 | — | — | — | — | 3 | — | — | — | — | — | 3 |
| Phase 3 | — | 1 | — | — | 2 | 1 | — | — | — | — | 4 |
| Phase 4 | — | — | — | — | 2 | 3 | — | — | 3 | — | 8 |
| Not applicable | 17 | 6 | 4 | 1 | 64 | 6 | — | 2 | 22 | — | 122 |
| Unknown | 19 | 6 | 2 | 5 | 65 | 2 | 2 | 2 | 17 | 1 | 121 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Celiac Disease | 5 | 21 | 7 | 34 | 3 | 4 | 8 | 122 | 121 | 325 |
| Crohn Disease | — | — | — | — | — | — | 1 | 7 | 16 | 24 |
| Irritable Bowel Syndrome | — | — | — | — | — | — | — | 10 | 14 | 24 |
| Colitis, Ulcerative | — | — | — | — | — | — | — | 3 | 13 | 16 |
| Inflammatory Bowel Diseases | — | — | — | — | — | — | 2 | 5 | 9 | 16 |
| Diabetes Mellitus, Type 1 | — | — | — | — | — | — | — | 3 | 9 | 12 |
| Autoimmune Diseases | — | 1 | — | 1 | — | — | — | 3 | 5 | 10 |
| Gastrointestinal Diseases | — | 1 | — | 1 | — | — | — | 4 | 4 | 10 |
| Intestinal Diseases | — | 1 | — | 1 | — | — | 2 | 4 | 2 | 10 |
| Multiple Sclerosis | — | — | — | — | — | — | — | 1 | 9 | 10 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | University of Palermo | 17 | 0 |
| 2 | Tampere University Hospital | 9 | 0 |
| 3 | 9 Meters Biopharma, Inc. | 8 | 1 |
| 4 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 8 | 0 |
| 5 | Hospital Mutua de Terrassa | 8 | 0 |
| 6 | Alvine Pharmaceuticals Inc. | 7 | 0 |
| 7 | Mayo Clinic | 7 | 0 |
| 8 | Oslo University Hospital | 7 | 1 |
| 9 | McMaster University | 6 | 0 |
| 10 | Takeda | 6 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Diet, Gluten-Free | 28 |
| 2 | Glutens | 20 |
| 3 | ALV003 | 8 |
| 4 | larazotide acetate | 8 |
| 5 | Endoscopy | 5 |
| 6 | Blood Specimen Collection | 4 |
| 7 | Flour | 3 |
| 8 | FODMAP Diet | 3 |
| 9 | Nexvax2 | 3 |
| 10 | Observation | 3 |
Evidence
- Results reported
- 10.3%19 of 184 completed
- Published
- 17.9%33 of 184 completed
- Primary endpoint met
- 25%4 of 16 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 73
- Median duration
- 25months
- Countries
- 38
- Study sites
- 1189
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 40
- Phase 1
- 23
- Phase 1/2
- 38
- Phase 2
- 80
- Phase 2/3
- 41
- Phase 3
- 208
- Phase 4
- 55
- Not applicable
- 50
- Unknown
- 161
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Boston | United States | 33 |
| 2 | Rochester | United States | 33 |
| 3 | New York | United States | 21 |
| 4 | Tampere | Finland | 20 |
| 5 | Palermo | Italy | 19 |
| 6 | Hamilton | Canada | 12 |
| 7 | Milan | Italy | 12 |
| 8 | Philadelphia | United States | 12 |
| 9 | Edmonton | Canada | 11 |
| 10 | Oslo | Norway | 11 |
Terminations
- Terminated
- 17
- Withdrawn
- 3
- Suspended
- 5
- Stopped for recruitment
- 2.2%7 of 325 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT04031469 Suspended | Suspended | Administrative | 2030-12-10 |
| NCT04148235 Withdrawn | Withdrawn | Company focus shifted | 2030-07-31 |
| NCT05119322 Suspended | Suspended | lack of resources | 2027-12-31 |
| NCT04306939 Suspended | Suspended | Suspended for analysis and to consider further enrollment. | 2026-12-31 |
| NCT05574010 Terminated | Terminated | Sponsor decision | 2025-05-19 |
| NCT05555446 Suspended | Suspended | Disengagement from sponsor, no funding provided since 2022. | 2025-01-01 |
| NCT03462979 Suspended | Suspended | covid-19 pandemic | 2023-12-31 |
| NCT05579444 Terminated | Terminated | Lack of enrollment. | 2023-11-29 |
| NCT04243551 Terminated | Terminated | Due to low enrollment related to Covid. | 2023-10-31 |
| NCT05114278 Terminated | Terminated | Study suspended due to a new development; the project was no longer feasible. | 2023-07-11 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: